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Previous studies have demonstrated the presence of cannabinoid 2 receptor (CB2R)
in the rat cochlea which was induced by cisplatin. In an organ of Corti-derived
cell culture model, it was also shown that an agonist of the CB2R protected these
cells against cisplatin-induced apoptosis. In the current study, we determined the
distribution of CB2R in the mouse and rat cochleae and examined whether these
receptors provide protection against cisplatin-induced hearing loss. In a knock-
in mouse model expressing the CB2R tagged with green fluorescent protein, we
show distribution of CB2R in the organ of Corti, stria vascularis, spiral ligament
and spiral ganglion cells. A similar distribution of CB2R was observed in the rat
cochlea using a polyclonal antibody against CB2R. Trans-tympanic administration
of (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH015), a selective
agonist of the CB2R, protected against cisplatin-induced hearing loss which was
reversed by blockade of this receptor with 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-
1H-indol-3-yl](4-methoxyphenyl)methanone (AM630), an antagonist of CB2R. JWH015
also reduced the loss of outer hair cells (OHCs) in the organ of Corti, loss of inner hair
cell (IHC) ribbon synapses and loss of Na+/K+-ATPase immunoreactivity in the stria
vascularis. Administration of AM630 alone produced significant hearing loss (measured
by auditory brainstem responses) which was not associated with loss of OHCs, but
led to reductions in the levels of IHC ribbon synapses and strial Na+/K+-ATPase
immunoreactivity. Furthermore, knock-down of CB2R by trans-tympanic administration
of siRNA sensitized the cochlea to cisplatin-induced hearing loss at the low and
middle frequencies. Hearing loss induced by cisplatin and AM630 in the rat was
associated with increased expression of genes for oxidative stress and inflammatory
proteins in the rat cochlea. In vitro studies indicate that JWH015 did not alter
cisplatin-induced killing of cancer cells suggesting this agent could be safely used
during cisplatin chemotherapy. These data unmask a protective role of the cochlear
endocannabinoid/CB2R system which appears tonically active under normal conditions
to preserve normal hearing. However, an exogenous agonist is needed to boost the
activity of endocannabinoid/CB2R system for protection against a more traumatic
cochlear insult, as observed with cisplatin administration.
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INTRODUCTION
Cisplatin is one of the main chemotherapeutic agents used to treat
different solid tumors including head and neck cancer, testicular
and ovarian cancer. However, cisplatin chemotherapy results
in dose-limiting toxicity to the cochlea, kidney, and peripheral
neurons. Hearing loss derives from the generation of significant
oxidative stress in the cochlea which results in part from the
activation and induction of a cochlear-specific NADPH oxidase
isoform, NOX3 (Banfi et al., 2004). The oxidative stress coupled
to the subsequent inflammatory processes and DNA damage
occurring in the cochlea promotes apoptosis and necrosis of the
sensory outer hair cells (OHCs) at the basal and middle regions
of cochlea (Estrem et al., 1981; Laurell and Bagger-Sjoback, 1991;
van den Berg et al., 2006; Rybak et al., 2007), damage to the stria
vascularis (SV) (Meech et al., 1998) and loss of spiral ganglion
neurons (SG) (Zheng et al., 1995; van Ruijven et al., 2005).
Currently, there are no drugs which are currently approved by
the US FDA for treating cisplatin-mediated hearing loss (Rybak
et al., 2009). We believe that a better understanding of the
mechanisms involved in ototoxicity and endogenous protective
signaling pathways could stimulate the development of effective
and novel otoprotective drugs.
Cannabinoid (CB) receptors include cannabinoid receptor
1 (CB1R), cannabinoid receptor 2 (CB2R), non-CB1/CB2Rs,
such as transient potential vanilloid 1 receptor (TRPV1), and
G protein-coupled receptor 55 (GPR55) (Console-Bram et al.,
2012). High levels of CB1R are expressed in the central nervous
system (CNS), while CB2R are predominantly expressed in
immune cells of the body including macrophages, leucocytes,
dendritic cells and natural killer cells (Console-Bram et al.,
2012). CB2R regulate the release of pro-inflammatory cytokines
such as interleukins (IL-1β, Il-6), tumor necrosis factor-α
(TNF-α), cyclooxygenase-2 (COX-2) and chemokines (CXCL8,
CCL2) from leucocytes and the differentiation of B and T
cells (Klein, 2005). CBs also suppress the activity of helper T
cells (Th1), increase the activity of Th2 cells (Klein, 2005) and
reduce leucocyte recruitment to the site of inflammation (Klein,
2005; Pacher et al., 2006). Activation of CB2R regulates the
cell growth and proliferation of immune cells and suppresses
macrophage growth and phagocytosis (Ashton and Glass, 2007).
Activation of endogenous cannabinoid receptors protects against
inflammatory diseases such as colonic inflammation in colitis
(Massa et al., 2004), rheumatoid arthritis (Zurier et al., 2003)
and autoimmune diabetes (Weiss et al., 2008). Endogenous
ligands for CB receptors, termed endocannabinoids, comprise
anandamide and 2-arachidonoyl glycerol (2-AG).
Previous studies have documented expression of CB2R
in immortalized House Ear Institute - Organ of Corti cell
line (HEI-OC1) which protected against cisplatin-induced cell
death (Jeong et al., 2007). A recent report showed that
CB2Rs are expressed in the rat cochlea and are induced by
cisplatin treatment (Martin-Saldana et al., 2016). However,
no functional role of these receptors was demonstrated. In
other disease models, upregulation of CB2R has been shown
to mediate an “autoprotective” role (Pertwee, 2009). Increased
expression of CB2R was observed in neuropathic pain models
(Zhang et al., 2003) and in rat sensory neurons during peripheral
nerve injury (Wotherspoon et al., 2005).
In the current study, we provide evidence that CB2R plays
a central role in regulating normal hearing, as inhibition or
knockdown of this receptor results in hearing loss. Furthermore,
trans-tympanic application of an agonist of CB2R protected
against cisplatin-induced hearing loss. These findings support
the conclusion that drugs targeting the CB2R could boost the





naphthalenylmethanone (JWH015), and antagonist,
6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-
methoxyphenyl)methanone (AM630), were purchased from
Tocris (#1341 and #1120, respectively). The different antibodies
used for this project were purchased from different vendors and
are as follows: CB2R (#Ab45942) and CB2R blocking peptide
(#Ab45941) from Abcam, antibody for Tuj1 was obtained from
Covance (#MMS-435P), while anti-CtBP2 was obtained from
BD Biosciences (#612044) and Anti-GluR2 was obtained from
Millipore (#MAB397). Antibody against Na+/K+-ATPase-α1
was obtained from Santa Cruz Biotechnology (#sc21712) while
Alexa FluorTM 488 Phalloidin antibody was obtained from
Thermo Fisher Scientific (#A12379). Two different myosin VIIa
antibodies were used for different purposes: Mouse IgG1 anti-
myosin-VIIa antibody was obtained from Developmental Studies
Hybridoma Bank (#138-1), while rabbit anti-myosin-VIIa was
purchased from Proteus Biosciences (#25-6790). Alexa Fluor
647 goat anti-rabbit antibody (#A21244), Alexa Fluor 488 goat
anti-rabbit antibody (#A11008), Alexa Fluor 647 goat anti-mouse
IgG1 antibody (#A21240), Alexa Fluor 568 goat anti-mouse
IgG2a antibody (#A21134) and Alexa 568 goat anti-mouse IgG1
antibody (#A21124) were obtained from Life Technologies.
Donkey anti-rabbit IRDye 680RD (#926-68073) and goat
anti-mouse IRDye 800RD (#926-32214) were from LI-COR
biosciences. Detailed description of the primary antibodies used
is provided in the Supplementary Table S1. For culturing cells,
RPMI1640 media was ordered from Gibco Life Technologies
(#11875085).
Animal Procedures
All the animals were housed in the Division of Laboratory Animal
Medicine (DLAM) facility of SIU School of Medicine and they
were provided with easy access to commercial food and water.
The rooms had controlled temperature and normal light/dark
cycles (12 h light/12 h dark). All experiments performed on
animals were approved and monitored by the Southern Illinois
University School of Medicine Laboratory Animal Care and Use
Committee.
Mice expressing the CB2R tagged with green fluorescent
protein (GFP) were kindly provided by Dr. Cecilia J. Hillard
(Department of Pharmacology and Toxicology, Medical College
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of Wisconsin). The mice (5–6 weeks old) were anesthetized
using isoflurane and sacrificed. Different organs including
cochlea, spleen and cerebellum were isolated and fixed in 4%
paraformaldehyde for 4–6 h in 4◦C, followed by washing in
10 mM PBS and stored at 4◦C until use.
Adult male Wistar rats (weight 200–250 g, 2–3 months old)
were purchased from Envigo (Indianapolis, IN, United States).
Rats were anesthetized with a mixture of ketamine (90 mg/kg)
and xylazine (17 mg/kg) and the depth of anesthesia was
determined by the absence of reflex to toe pinch which was
performed routinely during the duration of the procedure. If
the depth of anesthesis was determined to be insufficient, the
rats were administered additional dose of the mixture. Auditory
brainstem responses (ABRs) were performed on anesthetized
rats in a radio frequency concealed sound chamber just prior to
trans-tympanic JWH015 or AM630 treatments (for experimental
group) or PBS of pH 7.2 (for control groups). Cisplatin
(11 mg/kg) was administered via the intraperitoneal route and
post-treatment ABRs were measured 72 h later. At this point, the
animals were anesthetized using the same procedure mentioned
before and decapitated. One cochlea from each animal was
fixed using cochlear perfusion of 4% paraformaldehyde for
immunohistochemistry studies and the other cochlea was snap-
frozen for RNA extraction.
Auditory Brainstem Responses
Auditory evoked potentials were recorded as described
previously (Sheehan et al., 2018). Briefly the stainless steel
electrodes were positioned as follows: the ground electrode in the
rear flank, the positive electrode between the two ears directly
atop the skull, and the negative electrodes below the pinna
of each ear. Acoustic stimuli were delivered through inserted
earphones as a 5 ms tone burst at 8, 16, and 32 kHz and stimulus
intensities were determined as decibel sound pressure level (dB
SPL) which began at 10 dB SPL and reached ultimately 90 dB SPL
with a 10 dB step size. Threshold was defined as the lowest sound
intensity capable of evoking a reproducible, visually detectable
response with two distinct waveforms with minimum amplitudes
(II and III) of 0.5 µV. Threshold shift represents the difference
in threshold measured after treatment compared with threshold
obtained prior to treatment. Wave I was identified from the
neural responses and wave I amplitudes were documented from
the ABRs obtained from the different treatment groups.
Trans-Tympanic Administration of Drugs
and siRNA
Rats were anesthetized with ketamine/xylazine mixture. A single
trans-tympanic injection of the drug or siRNA was made in
the anterior–inferior region of rat tympanic membrane using
a 28–30 gauge needle (Sheehan et al., 2018). The position of
the needle was visualized using a Zeiss operating microscope
and 50 µl of solution was injected into the middle ear (siRNA
was resuspended in 50 µl of sterile water to get the desired
concentration). A similar procedure was performed 30 min later
on the other ear.
siRNA Sequences
The rat CB2R siRNA was purchased from Dharmacon as
an ON-TARGETplus SMARTpool siRNA which includes
a combination of four siRNA sequences against CB2R
RNA. The target sequence of CB2R siRNA included in this
combination are as follows: 5′-GCUUGGAGUUCAACCCUAU-
3′; 5′-CCAAUCAGCCUCCCUAAUA-3′; 5′-CUUGUUAACU
CCAUGAUCA-3′ and 5′-UGACCGCUGUUGACCGAUA-3′.
ON-TARGETplus Non-targeting Control siRNAs (scramble),
also purchased from Dharmacon, was used as negative
control.
Cochlear Whole-Mount Preparation
Isolated mice and rat cochleae were perfused with 4%
paraformaldehyde and kept overnight at 4◦C in the same solution
for fixation. Cochleae were then decalcified in 100 mM EDTA
(pH 7.3) with stirring at room temperature for 3 weeks for
rat cochlea and 4 days for mouse cochlea, respectively. The
decalcified cochleae were then microdissected into basal, middle
and apical turns for immunolabeling.
Immunohistochemistry
Decalcified cochleae were dissected and whole mount sections
were blocked, permeabilized in a mixture of 1% Triton X-100, 1%
BSA and 10% horse or goat serum depending on the host species
used for primary antibodies at room temperature for 1 h. They
were then incubated with primary antibodies diluted in a solution
containing 0.1% Triton X-100, 1% BSA and 10% horse or goat
serum. All primary antibodies were incubated at 4◦C overnight
on a rotator. The cochleae were then washed three times and
then placed in secondary antibodies, washed, mounted on slides
and used for imaging with Zeiss LSM800 scanning confocal
microscope. Mid-modiolar sections (10 µm thickness) of fixed
and decalcified cochlea were obtained by using a cryostat, which
were then dehydrated by incubating in 100% ethanol at −20◦C
for 20 min, followed by rehydration. These sections were stained
as above. Fluorescence intensity of the staining was quantified
using ImageJ software.
Hair Cell and Ribbon Synapse Count
The whole mount preparations of the cochlea samples were
labeled with antibodies against myosin VIIa, CtBP2, and GluR2
for labeling of hair cells, presynaptic RIBEYE and post-synaptic
glutamate receptors, respectively. The average hair cell counts
in each region were determined by manually counting cells in
the basal turn (100 µm length) of the cochlea. Normal counting
yield was 39–42 OHCs per 100 µm. The average number of
OHCs per three such regions taken at random from the base and
averaged to give the mean OHC count per animal per treatment
group. Functional ribbon synapses were defined as the number
of complexes showing both CtBP2 + GluR2 immunolabeling
apposing each IHC. At least 30 IHCs were used per sample to
provide an estimate of functional synapses per rat cochlea. At
least 3–4 animal cochleae were counted per group and used for
statistical comparisons.
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RNA Isolation and Real-Time RT-PCR
Total RNA was isolated from the cochlea as described previously
(Mukherjea et al., 2011). The purity and concentration of RNA
was determined by measuring the optical densities at 260, 280,
and 230 nm by a nanodrop spectrophotometer. The purified RNA
sample (260/230 ratios ranged from 1.8 to 2.0) were used for PCR.
PCR was performed using 500 ng of total RNA for gene specific
cDNA synthesis by using iScript Select cDNA Synthesis Kit (Bio-
Rad). The procedure used for real-time RT-PCR was described
previously (Mukherjea et al., 2011). The cycle threshold (Ct) was
determined by the number of cycles at which the samples reached
threshold fluorescent intensity. Negative controls were set up for
both the target and housekeeping gene, GAPDH, for all reaction
groups and no template cDNA was added to this mixture. The
relative change in mRNA levels between the vehicle and treated
group was quantified by the following formula: 211Ct (Soong
et al., 2001). The nucleotide sequences of rodent primer sets
were based on homologous sequences of rat and mouse cDNA
sequence. The primers were purchased from Sigma Genosys (St.




Rodent-TRPV1 (sense): 5′- CAAGGCTGTCTTCATCATCC-3′
(antisense): 5-AGTCCAGTTTACCTCG TCCA-3′ Rodent-
NOX3 (sense): 5′ GTGAACAAGGGAAGGCTCAT-3′ (anti-
sense): 5′-GACCCACAGAAGAACACGC-3′ Rodent-TNF-α
(sense): 5′-CAGACCCTCACACTCAGATCA-3′ (antisense): 5′-
TGAAGAGAACCTGGGAGTAGA-3′ Rodent-COX-2 (sense):
5′-TGATCGAAGACTACGTGCAAC-3′ (antisense): 5′-GTAC
TCCTGGTCTTCAATGTT-3′ and Rodent-iNOS (sense):
5′-CATTCTACTACTACCAGATC-3′ (antisense): 5′-ATGT




Immortalized mouse organ of Corti cells UB/OC-1 cells were
kindly provided by Dr. Matthew Holley (Institute of Molecular
Physiology, Western Bank, Sheffield, United Kingdom). Cells
were cultured in RPMI-1640 media supplemented with 10%
Fetalclone II serum (Hyclone), 5% penicillin–streptomycin
(Invitrogen) and normocin (InvivoGen). Cultures were grown
at 33◦C in a humidified incubator with 10% CO2. Head
and neck cancer cell line [University of Michigan squamous
carcinoma cells (UMSCC)10B], ovarian cancer cell (HeyA8) and
colon cancer cells (HCT116 WT) were cultured in RPMI-1640
media supplemented with 10% FBS (Atlanta Biologicals) and
5% penicillin-streptomycin at 37◦C and 5% CO2. Confluent
monolayer cells were used for experiments and cells were
cultured thrice a week for passaging.
Plasmid Transfection in UB/OC-1 Cells
Wild type CB2 receptor expressing pcDNA3.1 plasmids were
purchased from cDNA resource center. E. coli bacteria were
transformed with this plasmid and the transformed colonies were
selected by ampicillin resistance. DNA was isolated from the
transformed bacteria by maxi-prep (Qiagen) and transfected into
UB/OC1 cells by using Lipofectamine 3000 reagent (Invitrogen)
following the vendor’s protocol.
Immunocytochemistry
To detect the expression of CB2R in cells, UB/OC-1 cells were
plated in 24 well dishes on coverslips in complete media. The
confluent monolayer of cells was washed three times with ice-
cold 1X PBS and fixed with 4% paraformaldehyde for 15–20 min
at room temperature. The staining procedure was the same as
mentioned above for immunohistochemistry. The slides were
imaged by Zeiss LSM800 scanning confocal microscope.
MTS Assay for Cell Viability
In vitro cell viability of cancer cells following different drug
treatments was measured by using CellTiter 96 R© Aqueous One
Solution Cell Proliferation Assay kit (Promega). HeyA8 (2,000
cells per well), UMSCC10B and HCT116 WT (2,500 cells per
well) cells were plated in 96 well plate. The cells were treated with
JWH015 (10 µM) for 30 min followed by cisplatin (10 µM) for
48 h. At the end point, 20 µl of Cell Titer Aqueous One solution
reagent was added to each well containing 100 µl media. The
cells were incubated for at least 45 min in 33◦C and checked for
any color development and the plates were read at a wavelength
of 490 nm by Fluoroskan AscentTM FL Microplate Fluorometer
plate reader. For each cell line, experiments were repeated
independently at least three times and averages from independent
repeats were used for statistical analyses. The percentage of cell
viability was normalized against vehicle treated cells.
Statistical Analyses
The statistical significance differences were evaluated by using
either student’s t-test for two groups or Analysis of Variance
(ANOVA) with Tukey’s post hoc test for multiple treatment
groups using Graph Pad Prism software 6.0.
RESULTS
CB2 Receptors Are Expressed in the
Mouse and Rat Cochlea
CB2R immunolabeling in the rat cochlea has been reported
previously using commercially available CB2R antibody (Martin-
Saldana et al., 2016). However, the specificity of this antibody
is controversial (Baek et al., 2013). We therefore validated
the distribution of CB2R in the cochlea using a GFP-tagged
CB2R conditional knock-in mouse model using a commercially
available antibody. In the knock-in mice model, GFP was inserted
within exon 3 of the CB2R, and the expression of GFP was
driven by the endogenous CB2R promoter (Figure 1A). In mid-
modiolar sections of cochleae obtained from these mice, we show
endogenous GFP fluorescence in the organ of Corti (OC), spiral
ganglion (SG) neurons, stria vascularis (SV), and spiral ligament
(SL) (Figure 1B). We demonstrate the expression of GFP-CB2R
in the three rows of OHC and inner hair cells (IHC) in mid-
modiolar sections using co-immunolabeling of hair cells with
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FIGURE 1 | Distribution of the GFP-tagged CB2R knock-in mice. (A) The genetic background of the knock-in mice is shown where the GFP reporter gene was
inserted within exon 3 of CB2R and the expression of GFP was driven by internal ribosomal entry (IRE) promoter. Cochleae isolated from these GFP-CB2R
co-expressing knock-in mice were fixed in 4% paraformaldehyde followed by decalcification and then sectioned. (B) The representative mid-modiolar section shows
endogenous GFP fluorescence (green) in different anatomical regions of the cochlea including organ of Corti (OC), stria vascularis (SV), spiral ligament (SL), and spiral
ganglion (SG) neuron. (C) Immunolabeling of GFP-tagged CB2R (green) along with hair cell marker, Myo VIIa (red), show colocalization of CB2R in both, the OHCs
and IHCs. (D) Co-labeling of these cochleae with Tuj1 (red), a neuronal marker, show the distribution of GFP-CB2R (green) in spiral ganglion neurons. (E) Whole
mount sections of cochleae from GFP-CB2R co-expressing knock-in mice show co-localization of GFP-CB2R (green) and myosin VIIa (red) in the OHCs and IHCs of
OC. (F) GFP-CB2R whole mounts sections were also co-stained with neuronal marker, Tuj1 (red), and pre-synaptic ribbon marker, CtBP2 (magenta), showing
pre-synaptic localization of CB2R. Cell nuclei (blue) are stained with Hoechst stain in (B,E,F). Studies reported here were repeated in at least three different animals
and similar results were obtained.
myosin VIIa, a hair cell marker (Figure 1C). To demonstrate the
distribution of CB2R in cochlear neurons we used Tuj1, a mouse
monoclonal antibody for class III β-tubulin which labels both
Type I and Type II SG neurons in the rodent cochlea (Flores-
Otero et al., 2007; Lallemend et al., 2007; Barclay et al., 2011).
Immunolabeling with Tuj1 showed co-localization of GFP-CB2R
with Tuj1 in the soma or cell bodies (Figure 1D) and neurites
(Figure 1F) of SG neurons. Whole mount preparations show co-
localization of GFP-CB2R and myosin VIIa in the organ of Corti
(Figure 1E). Presynaptic localization of CB2R has previously
been shown in the autaptic hippocampal neurons (Atwood et al.,
2012). Therefore, we investigated the synaptic localization of
CB2R in the cochlea. Labeling with CtBP2, a presynaptic marker
for the IHCs, we show co-localization of endogenous GFP-tagged
CB2R and CtBP2 (Figure 1F).
CB2R from adult male Wistar rat cochleae were characterized
using a polyclonal antibody raised against amino acid residues
200–300 of this protein. This antibody was previously
characterized using blocking peptide controls, inclusion of which
resulted in no discernable signals in immunolabeling studies
(Supplementary Figure S1A). Using this antibody, we observed
high levels of immunolabeling in the rat spleen (which is rich
in CB2R), while low levels were detected in the hippocampus
(which normally show low levels of CB2R) (data not shown). In
addition, higher levels of CB2R were detected in Chinese hamster
ovary (CHO) cells which were transiently transfected with the
CB2R expression plasmid, as compared to cells transfected with
the empty plasmid vector alone (data not shown). Increased
CB2R immunoreactivity was also demonstrated in organ of
Corti-derived UB/OC-1 cells which were transiently transfected
with the CB2R plasmid (Supplementary Figure S1B). Using
this antibody for immunolabeling of rat cochlear sections,
we showed CB2R immunoreactivity in both the OHCs and
IHCs, inner (IPC) and outer pillar cells (OPC) (Figures 2A,B)
and SG neurons (Figure 2D). Mid-modiolar sections were
co-labeled with antibodies against Na+/K+-ATPase α1 subunit
and CB2R to investigate the expression of this receptor in the
SV. Intense CB2R immunolabelling was observed in the basal
cells of SV, as compared to the intermediate and marginal
cells (Figure 2C). CB2Rs were also distributed in Type II
fibrocytes of the SL (Figure 2C). Co-labeling of CB2R and
myosin VIIa was also detected in OHCs and IHCs of cochlear
whole mount preparations prepared from the rat cochleae
(Figure 2E).
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FIGURE 2 | Distribution of the CB2R in the rat cochlea. (A) Immunolabeling of mid-modiolar cochlear sections with CB2R antibody shows labeling of cells in the
organ of Corti (green). Labeling was observed in the outer hair cells (OHC), inner hair cells (IHC), inner pillar cell (IPC), and outer pillar cell (OPC). (B) Co-labeling of the
organ of Corti with antibodies for CB2R (green) and myosin VIIa (red) showed co-localization of these proteins in the OHC and IHC. (C) Staining of CB2R was also
observed in the intermediate and basal cells of the SV and type II fibrocytes in SL. CB2R (green) showed some overlap with Na+/K+-ATPase α1 subunit (red) in the
SV. (D) CB2R was localized to the plasma membranes of SG. Approximately 60% of cells in this section were stained with both CB2R (green) and Hoechst (blue).
(E) Co-labeling of CB2R and myosin VIIa in OHCs and IHCs in whole mount preparations of the organ of Corti shows that distribution of CB2R (green) is more
widespread than that of myosin VIIa (red). Hoechst was used as a nuclear stain (blue) in (B–E). Studies reported here were repeated in at least three different animals
and similar results were obtained.
Trans-Tympanic Administration of CB2R
Agonist Attenuated Cisplatin-Mediated
Hearing Loss and Loss of OHCs
Male Wistar rats were administered vehicle or JWH015
(2.5 nmoles in PBS per ear) by trans-tympanic injections,
followed 30 min later by intraperitoneal cisplatin (11 mg/kg)
administration. This dose of JWH015 produced optimal
otoprotection than lower doses of JWH015 tested and is
calculated to achieve a low micromolar range in the perilymph,
assuming a 1–10% entry of the drug from the middle ear
to the perilymph. Administration of vehicle produced no
change in ABR thresholds when compared to pre-treatment
ABRs (Figure 3A), attesting to the efficiency of the trans-
tympanic drug delivery. Cisplatin increased ABR thresholds
by 5.0 ± 1.5, 15.0 ± 2.5, and 27.0 ± 1.7 dB at 8, 16, and
32 kHz, respectively. Pretreatment with JWH015 diminished
ABR threshold shifts in all the three frequency regions. The ABR
threshold shifts were 0.6 ± 0.6, 1.9 ± 1.0, and 5.6 ± 1.5 dB
at 8, 16, and 32 kHz, respectively, for the JWH015 + cisplatin
treatment group. This protective action was completely blocked
by trans-tympanic administration of AM630 (2.5 nmoles in PBS
per ear), an antagonist of the CB2R (Morgan et al., 2009).
ABR threshold shifts induced by cisplatin in rats pretreated
with AM630 + JWH015 were 5.6 ± 1.2, 15.6 ± 2.4, and
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FIGURE 3 | Trans-tympanic administration of JWH015 prevents cisplatin-induced hearing loss. (A) Baseline ABR thresholds were recorded in Wistar rats, which
were then pre-treated with either trans-tympanic AM630 (2.5 nmoles) for 30 min followed by trans-tympanic JWH015 (2.5 nmoles) or individually with trans-tympanic
AM630 or JWH015 for 24 h. Cisplatin (11 mg/kg) was then administered (i.p.) after day 1 and post-ABR was performed after 72 h. Pre-treatment with JWH015
diminished cisplatin-induce ABR threshold shift in all the three frequency regions. The protective action of JWH015 was completely blocked by AM630.
Trans-tympanic administration of AM630 alone significantly elevated by ABR thresholds. Data (threshold shift) is plotted as mean ± SEM (n = 12). (B) The animals
were sacrificed at the end point and cochleae were collected, fixed by 4% PFA in PBS followed by decalcification for 3 weeks in 100 mM EDTA. The base of the
cochlea were dissected out and stained with hair cell marker, myosin VIIa, to determine the hair cell loss. Representative images are shown. Scale bar is 20 µm.
(C) The bar graph represents the average number of hair cells per 100 µm area shown in (B) (n ≥ 3). Pre-treatment with JWH015 reduced cisplatin-induced outer
hair cell loss. Administration of AM630 produced no hair cell loss. ∗p < 0.05 vs. vehicle; ∗∗p < 0.05 vs. cisplatin; #p < 0.05 vs. JWH015 + cisplatin; and ∗∗∗p < 0.05
vs. JWH015 (one-way ANOVA).
24.3 ± 3.1 dB at 8, 16, and 32 kHz, respectively, which were
similar to those obtained with cisplatin alone. An unexpected
finding was that trans-tympanic administration of AM630 alone
significantly elevated ABR thresholds by 5.8 ± 1.7, 11.9 ± 1.8,
and 18.1 ± 2.4 dB at 8, 16, and 32 kHz, respectively, compared
to vehicle-treated rats. Cisplatin-induced hearing loss was
associated with a reduction in OHC number, assessed at the basal
turn (Figures 3B,C). This loss of OHCs was reduced by trans-
tympanic JWH015 administration. Administration of AM630
alone did not produce any loss of OHCs nor did it enhance the
cell loss induced by cisplatin (Supplementary Figure S2). This
finding suggests that endogenous activation of the cochlear CB2R
(by endocannabinoids) helps in maintaining normal hearing and
that blockade of this tonic stimulation results in hearing loss.
Moreover, exogenous CB2 ligand can prevent cisplatin-induced
hearing loss.
CB2R Agonist Protected Against
Cisplatin-Induced Loss of IHC Ribbon
Synapse
Significant loss of ribbon synapses has been reported following
exposure to loud noise or treatment with aminoglycosides
(Kujawa and Liberman, 2009; Chen et al., 2012; Zhang et al.,
2013). Loss of ribbon synapses following noise exposure is
mediated by glutamate (Puel et al., 1998). A functional ribbon
synapse complex comprises a presynaptic ribbon containing
RIBEYE and post-synaptic glutamate receptors, such as GluR2
(Figure 4A). RIBEYE can be labeled by antibodies against
C-terminal binding protein 2 (CtBP2). In a recent report,
we demonstrated that CtBP2 immunoreactivity was decreased
following cisplatin treatment in rats and that this was abrogated
by pretreatment with EGCG (Borse et al., 2017). Here we show
that CB2R could also protect against cisplatin-induced loss of
ribbon synapses. Functional ribbon synapses were identified
as co-localization of both CtBP2 and GluR2 (Figure 4B). We
show a significant loss of functional ribbon synapse in the
basal turn from 20.9 ± 0.1 per IHC to 14.5 ± 0.2 per IHC,
following cisplatin treatment (Figures 4C,D). Pre-treatment
with JWH015 by trans-tympanic injection significantly reduced
cisplatin-mediated loss of functional synapses. The mean number
of functional synapses in JWH015 + cisplatin treated animal
was 18.5 ± 0.8. This finding suggests that CB2R protects both
the sensory hair cells and ribbon synapses, at least in the basal
turn of the cochlea, which could account for its overall efficacy
in reducing cisplatin ototoxicity. AM630 administered alone or
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FIGURE 4 | Activation of CB2R protects against cisplatin induced loss of ribbon synapse. (A) The cartoon represents a typical ribbon synapse at the inner hair cell
(IHC). It is primarily composed of two major components: presynaptic RIBEYE and glutamate receptors (GluR) at the post-synapse. (B) Representative images
shows whole mount preparations co-stained with presynaptic CtBP2 (for RIBEYE, magenta) and postsynaptic GluR2 (green). Functional ribbon synapses are
complexes showing both CtBP2 and GluR2 immunolabeling (white) apposing each IHC. (D) The whole mount preparation form the basal region of cochleae from
treated animals were dissected and stained for CtBP2 and GluR2. Representative images are shown. White arrows indicate single staining of either CtBP2 or GluR2.
Functional synapse complexes (CtBP2 + GluR2) were quantified by averaging the numbers from 30 IHCs per samples. The bar graph (C) represents the average
number of synaptic complexes (mean ± SEM) per IHC (n ≥ 4). Pre-treatment with JWH015 protected against cisplatin-induced loss of functional synapse. CB2R
antagonist, AM630, administered alone or in combination with JWH015 + cisplatin produced significant reductions in functional ribbon synapses. (E) ABR wave I
amplitude of different treatment groups at 60, 70, 80, and 90 dB SPL (32 kHz) was computed from sorted ABR wave forms. The bar graph represents mean wave I
amplitude ± SEM (n = 12). Cisplatin decreases wave I amplitude indicating synaptopathy which was completely reversed by pre-treatment with JWH015. Blockade
of CB2R activation by AM630 resulted in decrease in wave I amplitude. ∗p < 0.05 vs. vehicle; ∗∗p < 0.05 vs. cisplatin; and #p < 0.05 vs. JWH015 + cisplatin
(one-way ANOVA).
in combination with JWH015 + cisplatin produced significant
reductions in the number of ribbon synapses (15.6 ± 0.8
and 14.4 ± 0.4, respectively), compared to vehicle controls
(Figures 4C,D). These data suggest that synaptic ribbons are a
potential target of AM630 for mediating hearing loss, as this drug
did not produce any loss in OHCs. Thus, it appears that one of
the functions of endogenous cannabinoids in the cochlea is to
maintain the integrity of ribbon synapses which could contribute
significantly toward preserving normal hearing.
Synapse loss after acoustic trauma results in reductions in
supra-threshold amplitudes of wave I of the ABR (Bharadwaj
and Shinn-Cunningham, 2014). This phenomenon is considered
to be a good indicator of cochlear synaptopathy (Kujawa and
Liberman, 2009). Therefore, we determined whether cisplatin-
mediated cochlear synaptopathy is associated with change of
wave I supra-threshold amplitude. ABR wave I amplitude elicited
by 60–90 dB SPL tones delivered at 32 kHz were significantly
reduced by 33% (from 0.69 ± 0.03 µV to 0.46 ± 0.04 µV)
following cisplatin treatment (p < 0.0001, n = 12) (Figure 4E).
These decreases in wave I amplitudes were attenuated in rats
pretreated with trans-tympanic JWH015 prior to administration
of cisplatin (mean amplitude of wave I was 0.63 ± 0.03 µV),
suggesting that activation of CB2R in the cochlea regulates
cisplatin-induced cochlear loss of wave I amplitude. Rats treated
with AM630 alone or in combination of JWH015 + cisplatin
showed significantly diminished wave I amplitudes (mean
amplitude 0.46 ± 0.03 µV), compared to the control animals,
suggesting that CB2R activation provides tonic maintenance of
normal cochlear physiology.
Anti-inflammatory Role of CB2R in the
Cochlea
CB2Rs are primarily distributed in the immune cells where
they play a key role in the regulating both humoral and innate
immunity (Klein et al., 1998). These receptors suppress the
growth of macrophages and phagocytes and modulate the release
of inflammatory cytokines from leukocytes by regulating the
release of pro- and anti-inflammatory cytokines from helper
T cells, Th1 and Th2, respectively (Ashton and Glass, 2007).
Inflammation plays a critical role in cisplatin ototoxicity which
involves induction of pro-inflammatory cytokines by STAT1
(Kaur et al., 2011, 2016). Cisplatin increased the expression of
STAT1-regulated genes, such as TRPV1, NOX3, TNF-α, COX2,
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FIGURE 5 | Activation of CB2R by JWH015 mitigates cisplatin-induced inflammation in the rat cochlea. Snap frozen cochlea from treated animals were used for
total RNA extraction which was then converted to cDNA and used for real-time RT-PCR for the expression of TRPV1, NOX3, TNF-α, COX2, iNOS, and KIM1.
Housekeeping gene, GAPDH, was used for normalization. Cisplatin significantly increased the expression of all the genes tested. The expression of these genes
were significantly reduced in rats pre-treated with JWH015 followed by cisplatin. Administration of CB2R antagonist, AM630, alone increased the expression of
TRPV1, NOX3, and KIM1. Data is plotted as mean fold change ± SEM (n ≥ 5). ∗p < 0.05 vs. vehicle; ∗∗p < 0.05 vs. cisplatin; and #p < 0.05 vs. JWH015 + cisplatin
(one-way ANOVA).
iNOS, and KIM1 by 3.8 ± 0.5-, 2.3 ± 0.3-, 3.1 ± 0.3-, 3.7± 0.7-,
2.8 ± 0.5-, and 3.2 ± 0.2-fold, respectively, compared to
vehicle treated animals (Figure 5). These genes were significantly
reduced in rats pre-treated with JWH015 followed by cisplatin.
Interestingly, application of AM630 alone led to increased
expression of TRPV1, NOX3, and KIM1 by 2.6 ± 0.5, 1.8 ± 0.4
and 3.4 ± 0.1-fold, respectively, possibly indicating a functional
role of endocannabinoids targeting CB2Rs in dictating the basal
expression of these genes.
CB2R Maintains the Levels of
Na+/K+-ATPase in the Stria Vascularis
Na+/K+-ATPase present in the SV and SL fibrocytes plays
a critical role in maintaining endocochlear potential (EP)
in the cochlea (van Benthem et al., 1994; Wangemann,
2002). Recently we have shown that cisplatin reduces the
levels of this protein in SV and SL (Borse et al., 2017)
which might contribute to disruption of EP and hearing
loss. In this study, we determined whether activation of
CB2R could also attenuate cisplatin-induced loss of Na+/K+-
ATPase using an antibody which labels the α1 subunits of
this enzyme. We show that cisplatin reduced the level of
Na+/K+-ATPase in the SV which was abrogated by CB2R
activation (Figures 6A,B). Cisplatin reduced Na+/K+-ATPase
α1 immunoreactivity to 26.4 ± 5.2% of vehicle-treated controls,
which was attenuated in rats pretreated with JWH015 (labeling
was reduced to 96.9 ± 21.1% of vehicle-treated controls).
No significant change was observed in Na+/K+-ATPase α1
immunoreactivity in SV from rats treated with JWH015 alone.
Surprisingly, AM630 added alone reduced Na+/K+-ATPase α1
immunoreactivity to an extent which was comparable to cisplatin
(21.4 ± 3.6%). In addition, administration of AM630 blocked
the increase in Na+/K+-ATPase α1 immunoreactivity produced
by JWH015 in presence of cisplatin (38.4 ± 10%). These data
suggest that Na+/K+-ATPase could serve as another target
of cisplatin for inducing hearing loss which is regulated by
CB2R activation. Furthermore, the findings with AM630 lend
support to the conclusion that the basal expression and/or
distribution of this enzyme in the SV is strictly dependent on
CB2R.
Knockdown of CB2R in the Cochlea
Exacerbates Cisplatin-Induced Hearing
Loss
Trans-tympanic administration of CB2R siRNA produced dose-
dependent reduction in total cochlear CB2R mRNA within
48 h, as assessed by RT-PCR (Figure 7A). Approximately
80% reduction was observed at the highest dose of siRNA
(0.9 µg) used. Lower levels of siRNAs were less effective. At
48 h post siRNA administration, animals were administered
vehicle or cisplatin (11 mg/kg) by the intraperitoneal route.
Post-treatment ABRs were assessed 3 days later at 8, 16, and
32 kHz. As observed previously, cisplatin produced significant
ABR threshold shifts which increased with increasing sound
frequencies. Rats which were treated with CB2R siRNA, followed
by cisplatin, showed significantly increased threshold shifts
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FIGURE 6 | Activation of CB2R by JWH015 mitigates cisplatin-induced loss of Na+/K+-ATPase-α1 levels in the rat cochlea. (A) Mid-modiolar sections of the rat
cochlea were co-immunolabeled with Na+/K+-ATPase-α1 and phalloidin. The sections were imaged using Zeiss LSM800 scanning confocal microscope.
Representative images from the base of the cochlea are shown (n ≥ 3). (B) Bar graph represents % Na+/K+-ATPase fluorescence intensity ± SEM. Cisplatin
decreases expression of Na+/K+-ATPase-α1 in stria vascularis (SV) and spiral ligament (SL) and this is attenuated by pre-treatment with JWH015. AM630 added
alone also reduced Na+/K+-ATPase immunoreactivity which was similar to cisplatin. ∗p < 0.05 vs. vehicle; ∗∗p < 0.05 vs. cisplatin; and #p < 0.05 vs.
JWH015 + cisplatin (one-way ANOVA).
FIGURE 7 | Knock-down of CB2R expression by siRNA increases the sensitivity to cisplatin-induced hearing loss. (A) Rats were administered either scramble siRNA
(0.9 µg) or increasing doses of CB2R siRNA (0.3, 0.6, and 0.9 µg) by trans-tympanic injections. The animals were sacrificed 48 h later and mRNA was assessed for
CB2R expression by real-time RT-PCR. CB2R siRNA knocked down CB2R gene expression by ∼50 and ∼80% using 0.6 µg and 0.9 µg, respectively. Data are
represented as % expression ± SEM (n = 3). ∗p < 0.05 vs. scramble siRNA and ∗∗p < 0.05 vs. CB2R siRNA 0.6 µg. (B) Baseline ABR was recorded in rats
administered with either a scramble siRNA or CB2R siRNA by trans-tympanic injections for 48 h. Cisplatin (11 mg/kg, i.p.) was then administered and post-ABR was
recorded 72 h later. There was no significant change in ABR threshold shift in the animals treated with scramble siRNA or CB2R siRNA alone. Pre-treatment with
CB2 siRNA (0.9 µg) followed by cisplatin significantly potentiated cisplatin-induced hearing loss at 8 and 16 kHz. Data are represented as mean ± SEM. ∗p < 0.05
vs. scramble siRNA and ∗∗p < 0.05 vs. cisplatin (n = 6, one-way ANOVA).
at 8 and 16 kHz over those observed in the scrambled
siRNA plus cisplatin group. No difference was observed
at the 32 kHz frequency (Figure 7B). These results are
consistent with the conclusion that the endocannabinoid/CB2R
system in the cochlea can partially counter cisplatin-induced
ototoxicity in the 8 and 16 kHz frequency range. The
lack of effect at the high frequency (32 kHz) region of
the cochlea could reflect greater toxicity in the base of
the cochlea where cisplatin’s concentrations are the greatest
(Hellberg et al., 2013) and which overwhelms the protection
afforded by CB2R.
JWH015 Does Not Interfere With
Cisplatin Anti-cancer Efficacy in Cancer
Cells
Previous studies have shown that endogenous and synthetic
cannabinoids produce anti-cancer properties. For example,
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FIGURE 8 | Pre-treatment with JWH015 does not interfere with cisplatin
anti-cancer efficacy in vitro. Different cancer cells (UMSCC10B, HeyA8, and
HCT116 WT) were treated with JWH015 (10 µM) for 30 min followed by
cisplatin (10 µM) for 48 h. The cell viability was measured by MTS assay. The
percent cell viability is represented in the bar graph as mean ± SEM of at least
four independent experiments. ∗p < 0.05 represent significant difference from
vehicle-treated group at 100% (one-way ANOVA).
activation of CBRs induce apoptosis in cancer cells by the
classical cell death pathways (Olea-Herrero et al., 2009), induce
autophagy-mediated cell death (Salazar et al., 2009), arrest the
cell cycle and cell division (Laezza et al., 2006) or inhibit
neovascularization (Blazquez et al., 2003). We decided to
study whether CB2R agonists could interfere with cisplatin
chemotherapeutic effects in the event that these agents need
to be administered systemically to treat hearing loss. Several
cell lines derived from tumors known to be responsive to
cisplatin were examined. These include head and neck cancer
cells (UMSCC10B), ovarian cancer cells (HeyA8) and colon
cancer cells (HCT116 WT). Administration of 10 µM cisplatin
to cell cultures produced significant reductions in cell viability
which averaged 28.0 ± 5.1%, 52.1 ± 8.6%, and 62.6 ± 7.8% of
control cells, respectively, in UMSCC10B, HeyA8, and HCT116
WT cells (Figure 8). In cells pre-treated with 10 µM JWH015,
the percent cell viability in the JWH-015 + cisplatin group
were 22.0 ± 4.5, 56.4 ± 12.5, and 66.4 ± 10.6%, respectively,
in UMSCC10B, HeyA8, and HCT116 WT cells. These values
were not significantly different from those obtained with cisplatin
added alone, suggesting a lack of interference of cisplatin’s anti-
cancer response in presence of this CB2R agonist.
DISCUSSION
The current study demonstrates that CB2Rs are distributed
throughout the cochlea, including sensory hair cells, SG neurons,
SV and SL. Activation of CB2R by JWH015 protected against
cisplatin-induced hearing loss and this protective effect could
be completely blocked by AM630, an antagonist of CB2R.
Surprisingly, AM630 potentiated the ototoxicity produced by
cisplatin, especially at the low frequency range, and produced
significant hearing loss when administered alone. These data
suggest that activation of CB2Rs (by endocannabinoids) plays
a tonic protective role under normal condition and that
interference with these receptors or the endogenous cannabinoid
system could compromise hearing. In this regard, we observed
that knockdown of CB2R in the cochlea by siRNA exacerbated
cisplatin-induced hearing loss (at lower frequencies). In addition,
this study identified different cochlear targets of the CB2R
agonist, JWH015, which could account for its otoprotective
actions. These include the OHCs, ribbons synapses and stria
vascularis (Na+/K+-ATPase), regional targets which are shown
to express the CB2R subtype.
Systemic administration of cisplatin to the male Wistar rat
elevated ABR thresholds, which is especially evident in the
basal region of the cochlea. This loss of hearing in the high
frequency range was associated with a reduction in OHCs in the
basal turn of the cochlea and was attenuated by trans-tympanic
administration of JWH015, an agonist of the CB2R. JWH015
also protected against hearing loss in the lower frequency range,
even though these regions did not experience much discernable
damage or loss of OHCs. Thus, other mechanisms could account
for the “additional” protection afforded by CB2R in the low
frequency range.
Other targets of cisplatin’s action and CB2R-mediated
protection include functional ribbon synapses associated with the
IHCs. These synapses communicate the original auditory signal
generated by the IHCs to SG neurons. Alteration in the number
and/or function of these synapses would alter the auditory
transmission to SG neurons and central auditory pathways. The
reductions in ribbon synapses, or synaptopathy, observed in
cochleae obtained from cisplatin-treated rats would therefore
contribute to the overall elevations in ABR thresholds which were
observed. The basis for this synaptopathy induced by cisplatin
which has previously been described (Borse et al., 2017) is not
clear, but could result from glutamate excitotoxicity (Puel et al.,
1998). Cochlear synaptopathy resulting from noise exposure has
been previously described (Liberman, 2016). Previous studies
have reported that synapse loss in noise and age-induced
hearing loss (Sergeyenko et al., 2013; Espejo-Porras et al., 2015;
Liberman and Kujawa, 2017) which was not associated with
loss of OHCs or ABR threshold shifts. This type of cochlea
synaptopathy is known as “hidden hearing loss” (Liberman
and Kujawa, 2017) and is detected by a reduction in wave I
supra-threshold amplitude (Sredni et al., 2016; Liberman and
Kujawa, 2017). The present study revealed an important “tonic”
role of the endocannabinoid/CB2R system to preserve synaptic
integrity under normal condition which was unmasked by the
application of CB2R antagonist. Since noise-induced temporary
threshold shift and resulting synaptopathy is associated with
reductions in wave I amplitudes (Liberman, 2016), it is possible
that CB2R agonists could similarly protect against this deficit.
Whether activation of the CB2R could initiate regeneration of
synapses, following trauma, similar to neurotrophin 3 (Suzuki
et al., 2016), is not yet known. Unlike noise, cisplatin-induced
trauma results in permanent peripheral deficits which are not
restored by subsequent administration of protective agents. We
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observed a significant decrease in wave I amplitudes at 60,
70, 80, and 90 dB in the high frequency region (32 kHz)
in both cisplatin and AM630 treatment groups which reflect
synapse loss. The mechanism underlying the preservation of
synaptic integrity by pretreatment with CB2R agonist is not clear.
One possibility is that activation of presynaptic CB2R reduces
the release of excessive glutamate and this limits activation of
postsynaptic glutamate receptors and damage to the afferent
fibers. In support of this hypothesis, we observed co-localization
of CB2R and CtBP2 protein in the presynaptic nerve terminal
in the mouse cochlea. Previous studies have demonstrated a
role of presynaptic CB2R in autaptic hippocampal neurons
which mediate presynaptic inhibition of neurotransmitter release
(Atwood et al., 2012). In other disease models, upregulation
of CB2R has been shown to mediate an “autoprotective” role
(Pertwee, 2009). Increased expression of CB2R was observed in
neuropathic pain models (Zhang et al., 2003) and in rat sensory
neurons during peripheral nerve injury (Wotherspoon et al.,
2005).
While CB1Rs are expressed in the cochlea (unpublished
data), whether they are expressed in the IHC synapse and
to what extent they modulate afferent neurotransmission is
unknown. Nevertheless, in the CNS, CB1R plays a major role
in regulating presynaptic release of excitatory and inhibitory
neurotransmitters, such as GABA and glutamate (Pertwee, 2009).
A significant finding of this study is the observation that
perturbation of the endocannabinoid system in the cochlea
contributes to hearing loss. We showed that inhibition or
knockdown of CB2R resulted in elevations in ABR thresholds.
These findings suggest that the endocannabinoid system provides
a tonic level of protection to the cochlea which is only revealed
upon inhibition of this system with AM630. In addition to
the CBRs, we could detect labeling of the endocannabinoid 2-
AG synthetic enzyme, diacylglycerol lipase, to similar locations
in the cochlea (unpublished data). As such, 2-AG released
by cells in the cochlea would be able to activate CB2R on
the same or neighboring cells. Such an endogenous system
could contribute to cytoprotection under normal physiological
activity but could be overwhelmed by ototoxic drugs, such as
cisplatin. In such a situation, exogenously administered CB2R
agonist could be required to boost the protection afforded by
the endocannabinoid system. Another interesting observation
is that knockdown of CB2R by siRNA partly mimicked the
response to AM630, in that this perturbation sensitized these
animals to cisplatin-induced hearing loss at the lower frequencies.
These data would support the conclusion that endocannabinoids
(probably by acting through CB2R) help to maintain the integrity
of IHC ribbon synapse and protect hearing. Another explanation
is that in the presence of CB2R blockade the full effects of
endocannabinoids on other targets, such as CB1R and TRPV1
channels (Pertwee, 2009) are realized. Accordingly, activation of
these targets by endocannabinoids could confer ototoxicity.
The hearing loss produced by AM630 was not associated
with loss of OHCs and IHCs, but was more correlated with a
loss of IHC ribbon synapses. This would suggest that protecting
synaptic integrity and maintenance of EP are more important
roles of endocannabinoids than protecting the sensory hair cells.
Thus, the hearing loss produced by AM630 is partially different
from that produced by cisplatin, as the latter also mediates
apoptosis of hair cells. Changes in the EP have been associated
with acquired hearing loss including chemotherapeutic drugs,
age and noise-induced hearing loss (Schulte and Schmiedt, 1992;
Tsukasaki et al., 2000; Hirose and Liberman, 2003). Na+/K+-
ATPase present in the SV plays a critical role in generating
high K+ concentrations in the endolymph and in maintaining
the EP (Hibino et al., 2010). Increased oxidative stress has been
shown to decrease the activity of Na+/K+-ATPase by promoting
its proteolytic degradation and endocytosis (Chen et al., 2012).
Activation of CB2R protects against cisplatin-induced loss of
OHCs in the basal turn of the cochlea. This protection is similar
to that observed following activation of the adenosine A1 receptor
(Kaur et al., 2016), where it is linked to suppression of a NOX3
NADPH oxidase/STAT1 inflammatory pathway. It is believed
that inhibition of STAT1 in these OHCs attenuated cisplatin-
mediated p53 activation and apoptosis. Inhibition of STAT1 as
an otoprotective strategy has been documented in several studies
(Schmitt et al., 2009; Mukherjea et al., 2011; Kaur et al., 2016;
Borse et al., 2017). We showed that JWH015 suppressed cisplatin-
induced STAT1 activation in vitro, which could account for its
anti-apoptotic role in UB/OC-1 cell cultures (unpublished data).
A similar mechanism in vivo could account for the preservation
of OHCs in the basal turn of the cochlea. In support of this,
we show that JWH015 suppressed the induction of a number
of STAT1-regulated inflammatory genes, such as TNF-α, COX2,
and iNOS in whole cochlear extracts. The expression of NOX3
has been positively linked to activation of STAT1, as would be
expected from an increase in oxidative stress Kaur et al., 2016;
Borse et al., 2017).
CB2R plays a major role in regulating the immune system.
In addition to suppressing STAT1-dependent inflammatory
cytokines and related genes, activation of CB2R suppress the
recruitment of inflammatory cells to the site of inflammation.
(Klein, 2005). Activation of CB2R also suppress the proliferation
and phagocytotic function of macrophages (Ashton and Glass,
2007). CB2R agonist has also been shown to promote apoptosis of
immune cells (Lombard et al., 2007). Therefore, yet unexplored
actions of JWH015 in this study are its effects on the resident
immune cells and the recruitment and apoptosis of circulating
immune cells to the cochlea. Such actions would be expected to
reduce overall cochlear inflammation and reduce hearing loss.
We hope to explore these additional actions of CB2R in the
cochlea in the future.
Stimulation of CB2R can exert different effects on cancer cells
in a tissue and tumor specific manner (Velasco et al., 2016).
Various clinical studies have evaluated the role of cannabinoids
for palliative care in cancer patients to alleviate chemotherapy-
induced nausea and vomiting (Rock and Parker, 2016) and cancer
pain (Johnson et al., 2010). In this study, we show JWH015 does
not interfere with cisplatin’s anti-cancer efficacy in head and neck,
ovarian and colon cancer cells. These findings need to be further
studied in the xenograft mice model and other models before
systemic use of JWH015 could be initiated.
In summary, our data support a role of the
endocannabinoid/CB2R system in maintaining normal hearing
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in the rat cochlea. Protection stems from endocannabinoid/CB2R
interaction to maintain the integrity of OHCs, IHC
ribbon synapses and Na+/K+-ATPases in the SV. The
endocannabinoid/CB2R system is not fully able to protect
against cisplatin ototoxicity and requires addition of exogenous
CB2R agonist. This agonist protects against the loss of OHCs
and ribbon synapses. Trans-tympanic administration of CB2R
agonist provides effective protection against cisplatin-induced
hearing loss and should produce limited side effects of this
drug. Based on these results, we would recommend the use of
localized administration of CB2R agonists for the treatment of
cisplatin-induced hearing loss.
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FIGURE S1 | Characterization of the CB2R. (A) Specificity of CB2R
immunolabeling was confirmed in mid-modiolar sections using a blocking peptide
for the CB2R protein which revealed an absence of labeled proteins. (B) UB/OC1
cells were transiently transfected with a plasmid vector expressing CB2R. Cells
were fixed in 4% paraformaldehyde, washed with PBS and then immunolabeled
for CB2R (green). Labeling in the untransfected cells was confined to the plasma
membrane and was substantially increased following transient transfection of
CB2R.
FIGURE S2 | Administration of AM630 alone does not reduce OHC number and
did not alter the effect of cisplatin. The animals were sacrificed at the end point
and cochleae were collected, fixed by 4% PFA in PBS followed by decalcification
in 100 mM EDTA for 3 weeks. The base of the cochlea were dissected out and
stained with hair cell marker, myosin VIIa, to determine the hair cell loss.
Representative images are shown. Scale bar is 20 µm.
TABLE S1 | Description of antibodies used.
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